Search a Conference through our dedicated search page

Leucine Rich Repeat Kinase 2: Ten Years Along the Road to Therapeutic Intervention

11th July 2016   -   13th July 2016
Greenlands, United Kingdom


Mutations in Leucine Rich Repeat Kinase 2 are the most common genetic cause of Parkinsona€™s disease, making this multidomain enzyme one of the most promising drug targets for Parkinsona€™s. Following ten years of cellular research into LRRK2, this meeting will take stock of the current state of our understanding of the genetics, cellular function and pharmacology of LRRK2, and look to the future of drug development targeting this complex protein.

Related Fields